Home / Letter From The Editor / Dec. 13, 2016

Dec. 13, 2016

Dec 13, 2016


A few years ago Dr. Steven Nissen turned the diabetes world upside down when he went on a crusade to get TZD’s off the market due to cardiovascular risk. One of the results of his efforts was the FDA’s requirement that all new diabetes drugs would have extensive cardiovascular testing, which could potentially add years to the approval time. When the SGLT-2 Inhibitors were approved they all had to have these studies. One of these novel compounds had an effect that no one would have expected. It improved cardiovascular outcomes.

The EMPA-REG OUTCOME study showed how this was possible, and this week our Homerun Slides focus on this trial.

Dave Joffe